HepQuant-SHUNT检测预测肝硬化临床失代偿
本研究评估HepQuant-SHUNT检测对代偿期肝硬化患者失代偿、肝移植、住院及肝相关死亡的预测价值。35例代偿期和35例既往失代偿患者接受检测并随访中位4.2年,另在HALT-C队列84例代偿期肝硬化患者中验证。结果显示DSI≥24可区分失代偿与代偿患者,并独立预测不良临床结局(HR 4.92,95%CI 1.42-17.06);HALT-C队列中DSI≥24者65%发生不良结局,而DSI<24者仅19%(RR 3.45,P<0.0001)。
要点
- DSI≥24可区分代偿与失代偿肝硬化患者。
- DSI≥24独立预测失代偿、肝移植、死亡和住院风险。
- SHUNT检测是无创工具,有助于早期识别高风险患者。
核心结论
- SHUNT检测是一种新型无创检测,可预测既往代偿期肝硬化患者的失代偿风险。
- DSI≥24与临床失代偿、肝移植、死亡和住院风险独立相关。
研究设计与样本
- 研究纳入35例代偿期和35例既往失代偿的肝硬化患者,接受SHUNT检测并随访中位4.2年。
- 另在HALT-C试验中84例代偿期肝硬化患者中验证DSI对失代偿的预测价值,随访中位5.8年。
主要发现
- 基线时既往失代偿患者DSI显著高于代偿患者(32.6 vs 20.9,P < 0.001)。
- DSI≥24可区分失代偿与代偿患者,并独立预测不良临床结局(HR 4.92,95%CI 1.42-17.06)。
- HALT-C队列中,基线DSI≥24者65%发生不良临床结局,而DSI<24者仅19%(RR 3.45,P < 0.0001)。
关键数值与推荐
- DSI范围0-50,DSI≥24为区分失代偿与代偿患者的阈值。
- DSI≥24独立预测不良临床结局的HR为4.92(95%CI 1.42-17.06)。
- HALT-C队列中DSI≥24者不良结局发生率65%,DSI<24者19%,RR 3.45(P < 0.0001)。
临床怎么用
- 对于临床稳定的代偿期肝硬化患者,可考虑使用SHUNT检测评估失代偿风险。
- DSI≥24提示高风险,可帮助专科医生早期干预并优化转诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early identification of risk for decompensation in clinically stable cirrhotic patients helps specialists target early interventions and supports effective referrals from primary care providers to specialty centres. AIMS: To examine whether the HepQuant-SHUNT test (HepQuant LLC, Greenwood Village, Colorado, USA) predicts decompensation and the need for liver transplantation, hospitalisation or liver-related death. METHODS: Thirty-five compensated and 35 subjects with a previous episode of decompensation underwent the SHUNT Test and were followed for a median of 4.2 years. The disease severity index (DSI) (range 0-50) was examined for association with decompensation in compensated patients; and liver transplantation, liver-related death, and the number and days of liver related hospitalisations in all. DSI prediction of decompensation was also evaluated in 84 subjects with compensated cirrhosis from the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial (HALT-C) followed for a median of 5.8 years. RESULTS: At baseline, subjects with prior decompensation had significantly higher DSI than compensated subjects (32.6 vs 20.9, P < 0.001). DSI ≥24 distinguished the decompensated from the compensated patients and independently predicted adverse clinical outcomes (hazard ratio: 4.92, 95% confidence interval: 1.42-17.06). In the HALT-C cohort, 65% with baseline DSI ≥24 vs 19% with DSI <24 experienced adverse clinical outcomes (relative risk 3.45, P < 0.0001). CONCLUSIONS: The SHUNT test is a novel, noninvasive test that predicts risk of decompensation in previously compensated patients. DSI ≥24 is independently associated with risk for clinical decompensation, liver transplantation, death and hospitalisation.
引用
- Fallahzadeh MA, Hansen DJ, Trotter JF, et al. Predicting clinical decompensation in patients with cirrhosis using the Hepquant-SHUNT test. Aliment Pharmacol Ther. 2021. PMID: 33556192. doi:10.1111/apt.16283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。